S&P 5007,736.52▲1.8% Nasdaq26,584.99▲2.6% Dow54,085.88▲1.7% Russell 2K3,036.98▲1.9% 10-Yr4.63%−6bp VIX16.50+0.64 WTI$75.32▼6.2% Gold$4,133.60▲2.5% EUR/USD1.153▼0.1% BTC$64,263▲1.3% Nikkei63,755▼0.9%
At close · Tue, Aug 4, 2026
Daily Market Updates.

Earnings

Home›Earnings›Previews›Novo Nordisk raises forecast, but obesity growth debat…

Novo Nordisk raises forecast, but obesity growth debate persists

Investors remain cautious that the company can restore sustainable growth as competition from Eli Lilly keeps pressure on the obesity market.

Reported · Written up by our desk · Previews

CNBC Markets reports that Novo Nordisk lifted its forecast, but the change did not resolve Wall Street concerns about the company’s path to sustainable growth from its obesity franchise.

The coverage highlights that sentiment is being shaped by intensifying competition from Eli Lilly, which continues to weigh on how investors view Novo Nordisk’s long-term momentum in the obesity business.

← Newer storyDollar index slips as investors temper near-term Fed hike bets

More like this

EarningsWhat to watch ahead of Disney's earnings before the bell
EarningsChipotle removes jalapenos from some locations after salmonella probe
EarningsPalantir targets continued revenue acceleration as U.S. growth remains key
EarningsNovo Nordisk shares fall after Wegovy miss and outlook update
EarningsKey stocks set for earnings week as option volatility spikes

Sources

CNBC MarketsNovo Nordisk's raised forecast fails to change the debate over its obesity business
CNBC WorldNovo Nordisk's raised forecast fails to change the debate over its obesity business
CNBC EarningsNovo Nordisk's raised forecast fails to change the debate over its obesity business

Get the close, explained.

One email every trading day: what moved, why it moved, and what's on deck tomorrow. Read in 3 minutes.

Free. Unsubscribe anytime.